Zydus Cadila launches affordable drug for prostate cancer therapy

Zydus Cadila today informed the bourses that it has launched Enzalutamide, a highly effective drug for the treatment of prostate cancer, under the brand name ‘Obnyx’ in India. With this launch, the treatment cost of prostate cancer is likely to be reduced by almost 70 per cent, costing around Rs 5,995 for weekly therapy, resulting in saving nearly Rs 27,000, the company said in its exchange filing.

The current MRP of Enzalutamide drug ranges from Rs 70,000 to Rs 80,000 for a monthly therapy and this therapy will continue for a long period of time thus, the launch of this product is expected to be a huge booster for the company.

Prostate cancer is one of the leading cancers in males in India and the risk increases with age. About one out of nine men have a risk of developing prostate cancer in a lifetime. The company has developed in-house and the drug offers bio-availability advantages in a soft gel capsule, different from the hard gelatin capsules available in India.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines.